bioAffinity Technologies Inc
BIAF1.240USD
+0.010+0.81%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.30MMarket Cap
LossP/E TTM
More Details of bioAffinity Technologies Inc Company
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
bioAffinity Technologies Inc Info
Ticker SymbolBIAF
Company namebioAffinity Technologies Inc
IPO dateAug 26, 2022
CEOZannes (Maria)
Number of employees57
Security typeOrdinary Share
Fiscal year-endAug 26
Address3300 Nacogdoches Road
CitySAN ANTONIO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78217
Phone12106985334
Websitehttps://bioaffinitytech.com/
Ticker SymbolBIAF
IPO dateAug 26, 2022
CEOZannes (Maria)
Company Executives of bioAffinity Technologies Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James Michael Edwards, CPA
Mr. James Michael Edwards, CPA
Chief Financial Officer
Chief Financial Officer
120.13K
--
Mr. Steven Girgenti
Mr. Steven Girgenti
Executive Chairman of the Board
Executive Chairman of the Board
36.30K
-0.01%
Ms. Maria Zannes, J.D.
Ms. Maria Zannes, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.67K
-47.83%
Mr. Peter S. Knight
Mr. Peter S. Knight
Independent Director
Independent Director
2.58K
-34.07%
Mr. Roberto Rios, CPA
Mr. Roberto Rios, CPA
Director
Director
833.00
+2875.00%
Dr. John J. Oppenheimer, M.D.
Dr. John J. Oppenheimer, M.D.
Director
Director
--
--
Mr. Robert Anderson
Mr. Robert Anderson
Independent Director
Independent Director
--
--
Dr. Jamie Platt, Ph.D.
Dr. Jamie Platt, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Overton
Ms. Julie Anne Overton
Director of Communications
Director of Communications
--
--
Dr. William Bauta, Ph.D.
Dr. William Bauta, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James Michael Edwards, CPA
Mr. James Michael Edwards, CPA
Chief Financial Officer
Chief Financial Officer
120.13K
--
Mr. Steven Girgenti
Mr. Steven Girgenti
Executive Chairman of the Board
Executive Chairman of the Board
36.30K
-0.01%
Ms. Maria Zannes, J.D.
Ms. Maria Zannes, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.67K
-47.83%
Mr. Peter S. Knight
Mr. Peter S. Knight
Independent Director
Independent Director
2.58K
-34.07%
Mr. Roberto Rios, CPA
Mr. Roberto Rios, CPA
Director
Director
833.00
+2875.00%
Dr. John J. Oppenheimer, M.D.
Dr. John J. Oppenheimer, M.D.
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sabby Management, LLC
5.40%
Crumly (Richard K)
1.34%
Bigger Capital Funds, LP
1.30%
District 2 Capital LP
1.30%
Girgenti (Steven)
0.81%
Other
89.85%
Shareholders
Shareholders
Proportion
Sabby Management, LLC
5.40%
Crumly (Richard K)
1.34%
Bigger Capital Funds, LP
1.30%
District 2 Capital LP
1.30%
Girgenti (Steven)
0.81%
Other
89.85%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
5.40%
Individual Investor
2.70%
Hedge Fund
2.66%
Investment Advisor
0.68%
Family Office
0.57%
Corporation
0.45%
Research Firm
0.04%
Other
87.49%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
37
395.18K
0.39%
--
2025Q3
37
395.18K
0.60%
+382.14K
2025Q2
31
13.04K
1.99%
-3.54K
2025Q1
26
16.58K
3.19%
-2.81K
2024Q4
23
17.52K
3.71%
+2.26K
2024Q3
24
15.26K
3.78%
+2.27K
2024Q2
24
12.99K
3.07%
+5.17K
2024Q1
21
7.82K
2.21%
-425.00
2023Q4
17
5.04K
2.39%
+752.00
2023Q3
16
4.28K
2.41%
+87.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Crumly (Richard K)
60.25K
2.08%
+60.25K
--
May 07, 2025
Bigger Capital Funds, LP
58.68K
2.02%
+58.68K
--
Sep 29, 2025
District 2 Capital LP
58.68K
2.02%
+58.68K
--
Sep 29, 2025
Girgenti (Steven)
36.30K
1.25%
--
--
May 29, 2025
The Joyce Living Trust
19.44K
0.67%
+667.00
+3.55%
May 29, 2025
The Vanguard Group, Inc.
1.35K
0.05%
-4.54K
-77.02%
Jun 30, 2025
Zannes (Maria)
12.79K
0.44%
+3.45K
+36.95%
May 29, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 17, 2025
Merger
30→1
Date
Type
Ratio
Sep 17, 2025
Merger
30→1
FAQs
Who are the top five shareholders of bioAffinity Technologies Inc?
The top five shareholders of bioAffinity Technologies Inc are:
Crumly (Richard K) holds 60.25K shares, accounting for 2.08% of the total shares.
Bigger Capital Funds, LP holds 58.68K shares, accounting for 2.02% of the total shares.
District 2 Capital LP holds 58.68K shares, accounting for 2.02% of the total shares.
Girgenti (Steven) holds 36.30K shares, accounting for 1.25% of the total shares.
The Joyce Living Trust holds 19.44K shares, accounting for 0.67% of the total shares.
Crumly (Richard K) holds 60.25K shares, accounting for 2.08% of the total shares.
Bigger Capital Funds, LP holds 58.68K shares, accounting for 2.02% of the total shares.
District 2 Capital LP holds 58.68K shares, accounting for 2.02% of the total shares.
Girgenti (Steven) holds 36.30K shares, accounting for 1.25% of the total shares.
The Joyce Living Trust holds 19.44K shares, accounting for 0.67% of the total shares.
What are the top three shareholder types of bioAffinity Technologies Inc?
The top three shareholder types of bioAffinity Technologies Inc are:
Sabby Management, LLC
Crumly (Richard K)
Bigger Capital Funds, LP
Sabby Management, LLC
Crumly (Richard K)
Bigger Capital Funds, LP
How many institutions hold shares of bioAffinity Technologies Inc (BIAF)?
As of 2025Q4, 37 institutions hold shares of bioAffinity Technologies Inc, with a combined market value of approximately 395.18K, accounting for 0.39% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.21%.
What is the biggest source of revenue for bioAffinity Technologies Inc?
In --, the -- business generated the highest revenue for bioAffinity Technologies Inc, amounting to -- and accounting for --% of total revenue.
